These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 30596678)
1. Ultrasonic cavitation induces necrosis and impairs growth in three-dimensional models of pancreatic ductal adenocarcinoma. Abou Ali E; Bordacahar B; Mestas JL; Batteux F; Lafon C; Camus M; Prat F PLoS One; 2018; 13(12):e0209094. PubMed ID: 30596678 [TBL] [Abstract][Full Text] [Related]
2. Ultrasound-induced Cavitation enhances the efficacy of Chemotherapy in a 3D Model of Pancreatic Ductal Adenocarcinoma with its microenvironment. Leenhardt R; Camus M; Mestas JL; Jeljeli M; Abou Ali E; Chouzenoux S; Bordacahar B; Nicco C; Batteux F; Lafon C; Prat F Sci Rep; 2019 Dec; 9(1):18916. PubMed ID: 31831785 [TBL] [Abstract][Full Text] [Related]
3. Cellular context-dependent interaction between cancer and stellate cells in hetero-type multicellular spheroids of pancreatic tumor. Nam S; Khawar IA; Park JK; Chang S; Kuh HJ Biochem Biophys Res Commun; 2019 Jul; 515(1):183-189. PubMed ID: 31133378 [TBL] [Abstract][Full Text] [Related]
4. Anti-stromal treatment together with chemotherapy targets multiple signalling pathways in pancreatic adenocarcinoma. Carapuça EF; Gemenetzidis E; Feig C; Bapiro TE; Williams MD; Wilson AS; Delvecchio FR; Arumugam P; Grose RP; Lemoine NR; Richards FM; Kocher HM J Pathol; 2016 Jul; 239(3):286-96. PubMed ID: 27061193 [TBL] [Abstract][Full Text] [Related]
5. Expression of gemcitabine metabolizing enzymes and stromal components reveal complexities of preclinical pancreatic cancer models for therapeutic testing. Knoll L; Hamm J; Stroebel P; Jovan T; Goetze R; Singh S; Hessmann E; Ellenrieder V; Ammer-Herrmenau C; Neesse A Neoplasia; 2024 Jul; 53():101002. PubMed ID: 38744194 [TBL] [Abstract][Full Text] [Related]
6. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer. Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152 [TBL] [Abstract][Full Text] [Related]
7. Prolactin receptor potentiates chemotherapy through miRNAs-induced G6PD/TKT inhibition in pancreatic cancer. Liao YN; Huang PQ; Pan H; Gai YZ; Zhan YF; Li SX; Nie HZ FASEB J; 2024 May; 38(10):e23705. PubMed ID: 38805171 [TBL] [Abstract][Full Text] [Related]
8. pH-responsive targeted nanoparticles release ERK-inhibitor in the hypoxic zone and sensitize free gemcitabine in mutant K-Ras-addicted pancreatic cancer cells and mouse model. Dutta D; Ray P; De A; Ghosh A; Hazra RS; Ghosh P; Banerjee S; Diaz FJ; Upadhyay SP; Quadir M; Banerjee SK PLoS One; 2024; 19(4):e0297749. PubMed ID: 38687749 [TBL] [Abstract][Full Text] [Related]
9. Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer. Liu Y; Li F; Gao F; Xing L; Qin P; Liang X; Zhang J; Qiao X; Lin L; Zhao Q; Du L Tumour Biol; 2016 Nov; 37(11):15283-15291. PubMed ID: 27696296 [TBL] [Abstract][Full Text] [Related]
10. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer. Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599 [TBL] [Abstract][Full Text] [Related]
11. The anti-fibrotic effect of GV1001 combined with gemcitabine on treatment of pancreatic ductal adenocarcinoma. Park JK; Kim Y; Kim H; Jeon J; Kim TW; Park JH; Hwnag YI; Lee WJ; Kang JS Oncotarget; 2016 Nov; 7(46):75081-75093. PubMed ID: 27655706 [TBL] [Abstract][Full Text] [Related]
12. Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II. Awasthi N; Zhang C; Hinz S; Schwarz MA; Schwarz RE J Exp Clin Cancer Res; 2013 Mar; 32(1):12. PubMed ID: 23497499 [TBL] [Abstract][Full Text] [Related]
13. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma. Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352 [TBL] [Abstract][Full Text] [Related]
14. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia. McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621 [TBL] [Abstract][Full Text] [Related]
15. Effect of hyperbaric oxygenation and gemcitabine on apoptosis of pancreatic ductal tumor cells in vitro. Bosco G; Guizzon L; Yang Z; Camporesi E; Casarotto A; Bosio C; Mangar D; Chen C; Cannato M; Toniolo L; Garetto G; Nasole E; Bassi C Anticancer Res; 2013 Nov; 33(11):4827-32. PubMed ID: 24222119 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine. Xu D; Cobb MG; Gavilano L; Witherspoon SM; Williams D; White CD; Taverna P; Bednarski BK; Kim HJ; Baldwin AS; Baines AT Cancer Biol Ther; 2013 Jun; 14(6):492-501. PubMed ID: 23760491 [TBL] [Abstract][Full Text] [Related]
17. A novel 3-dimensional culture system uncovers growth stimulatory actions by TGFβ in pancreatic cancer cells. Sempere LF; Gunn JR; Korc M Cancer Biol Ther; 2011 Aug; 12(3):198-207. PubMed ID: 21613822 [TBL] [Abstract][Full Text] [Related]
18. Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma. Kubo M; Gotoh K; Eguchi H; Kobayashi S; Iwagami Y; Tomimaru Y; Akita H; Asaoka T; Noda T; Takeda Y; Tanemura M; Mori M; Doki Y Ann Surg Oncol; 2020 Feb; 27(2):610-619. PubMed ID: 31605325 [TBL] [Abstract][Full Text] [Related]
19. Suppression of STAT5b in pancreatic cancer cells leads to attenuated gemcitabine chemoresistance, adhesion and invasion. Sumiyoshi H; Matsushita A; Nakamura Y; Matsuda Y; Ishiwata T; Naito Z; Uchida E Oncol Rep; 2016 Jun; 35(6):3216-26. PubMed ID: 27035235 [TBL] [Abstract][Full Text] [Related]
20. Molecular analysis of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in KPC pancreatic cancer mouse model. Uddin MH; Al-Hallak MN; Khan HY; Aboukameel A; Li Y; Bannoura SF; Dyson G; Kim S; Mzannar Y; Azar I; Odisho T; Mohamed A; Landesman Y; Kim S; Beydoun R; Mohammad RM; Philip PA; Shields AF; Azmi AS Clin Transl Med; 2023 Dec; 13(12):e1513. PubMed ID: 38131168 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]